FDA
-
-
-
-
-
-
-
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
-
-
-
-
-
-
-
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on AN2 Therapeutics (ANTX)
-
-
-
-
-
-
-
TD Cowen Downgrades AN2 Therapeutics (ANTX) to Hold
-
-
-
-
-
-
-
AN2 Therapeutics (ANTX) to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Trial of Epetraborole
-
-
-
-
-
-
-
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
-
-
-
-
-
-
322,086 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

